Statin use | Univariate analysis (n = 63,605, GC = 169) | PS matching^{a} (n = 22,870, GC = 62) | PS adjustment^{a} (n = 57,243, GC = 150) | Multivariable analysis (n = 63,605, GC = 169) | ||||
---|---|---|---|---|---|---|---|---|

All GC | SHR (95% CI) | P value | SHR (95% CI) | P value | SHR (95% CI) | P value | SHR (95% CI) | P value |

Nonstatin use | Ref | — | Ref | — | Ref | — | Ref | — |

Statin use | 0.61 (0.41–0.92) | 0.020 | 0.34 (0.19–0.61) | <0.001 | 0.33 (0.18–0.59) | <0.001 | 0.44 (0.28–0.68) | <0.001 |

Noncardia GC | (n = 63,571, GC = 135) | (n = 22,865, GC = 36) | (n = 57,123, GC = 120) | (n = 63,571, GC = 135) | ||||

SHR (95% CI) | P value | SHR (95% CI) | P value | SHR (95% CI) | P value | SHR (95% CI) | P value | |

Nonstatin use | Ref | — | Ref | — | Ref | — | Ref | — |

Statin use | 0.56 (0.35– 0.90) | 0.017 | 0.48 (0.24– 0.98) | 0.044 | 0.33 (0.17– 0.65) | 0.001 | 0.46 (0.27– 0.74) | 0.002 |

Cardia GC | (n = 63,470, GC = 34) | (n = 22,865) GC = 15) | (n = 57,123, GC = 30) | (n = 63,470, GC = 34) | ||||

SHR (95% CI) | P value | SHR (95% CI) | P value | SHR (95% CI) | P value | SHR (95% CI) | P value | |

Nonstatin use | Ref | — | Ref | — | Ref | — | Ref | — |

Statin use | 0.83 (0.39–1.90) | 0.660 | n.a.^{b} (n.a.^{b}) | n.a.^{b} | 0.31 (0.09– 1.03) | 0.055 | n.a.^{b} (n.a.^{b}) | n.a.^{b} |

Note: Statin use was defined as use for more than 180 days.

Abbreviations: GC, gastric cancer; SHR, subdistribution hazard ratio.

↵

^{a}PS analysis was performed after trimming of the extreme PS strata (5th and 95th percentiles).↵

^{b}SHR could not be calculated as the estimation procedure for fitting the subdistribution hazard model failed to converge.